Clinical Trials Sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics
Total 12 results
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSingle-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma MultiformeGlioblastoma MultiformeIsrael, United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedGlioblastomaUnited States, Israel, Canada
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedUlcerative ColitisPoland, Bulgaria, Hungary
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPsoriasisGermany, Israel, Poland, Spain
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPlatinum Resistant Ovarian CancerUnited States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsUnknownAdvanced and/or Metastatic Solid Organ CancerUnited States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedBiomarkerUnited Kingdom
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedDifferential Thyroid CancerUnited States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedActive Plaque PsoriasisUnited States, Germany, Israel
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsGOG FoundationCompletedRecurrent Platinum Resistant Ovarian CancerUnited States, Israel, Japan, Poland, Spain
-
Dana-Farber Cancer InstituteVascular Biogenics Ltd. operating as VBL TherapeuticsActive, not recruitingGlioblastoma | Recurrent GlioblastomaUnited States